10 Stocks That Just Hit Analysts’ Desks

Page 3 of 3

4. Alector (NASDAQ:ALEC)

Average Upside Potential: 74%

Number of Hedge Fund Holders: 25

Wells Fargo initiated coverage of Alector (NASDAQ:ALEC) on November 13 with an Overweight rating and a $7 price target. The firm says sentiment on the stock is negative after setbacks in its progranulin program and expects clinical data for its AL137 antibody to close the valuation gap. Alector, based in South San Francisco, is a clinical-stage biotech that develops treatments aimed at the immune system of the brain.

Wells Fargo’s case rests on a transferrin receptor approach to getting drugs into the brain for Alzheimer’s disease. The company’s third quarter of 2026, reported on November 5, added money behind it. Genentech took an exclusive global license to AL050, paying $100 million upfront with up to $1.17 billion in milestone payments to come.

Alector ended the third quarter of 2026 on September 30 with $138.7 million in cash, cash equivalents and investments, which the company says funds operations into the second half of 2029. AL137 has not yet been given to people. Alector plans first-in-human dosing in Australia no later than April 2027, so the data Wells Fargo is waiting for are still a long way off.

3. Denali Therapeutics (NASDAQ:DNLI)

Average Upside Potential: 91%

Number of Hedge Fund Holders: 35

Wells Fargo initiated coverage of Denali Therapeutics (NASDAQ:DNLI) with an Overweight rating and a $35 price target on November 13, calling this an inflection point for the company’s transferrin receptor technology. Denali, based in San Francisco, develops drugs for neurodegenerative diseases, with a pipeline that includes programs aimed at LRRK2, RIPK1, TREM2 and Tau.

The firm points to the approval of Avlayah, constructive FDA feedback on zafinofusp and Roche’s trontinemab data as validation of that approach, and it says cash flows from Avlayah and zafinofusp give the stock a floor value. Sales are early but climbing, and the company reported them on November 3. Avlayah brought in $17.8 million in net product revenue in the third quarter of 2026, its second full commercial quarter, and the company guided to $30.0 million to $32.0 million for the fourth quarter of 2026. The company also said coverage reaches above 70% of US commercial lives.

Wells Fargo is cautious on one front. It sees Hunter syndrome and Sanfilippo syndrome as small markets and Alzheimer’s as more competitive, with little room to stand apart from Roche’s trontinemab. Denali ended the third quarter of 2026 with about $1.01 billion in cash, cash equivalents and marketable securities.

2. INNIO (NASDAQ:INIO)

Average Upside Potential: 108%

Number of Hedge Fund Holders: 55

Piper Sandler initiated coverage of INNIO (NASDAQ:INIO) on November 13 with an Overweight rating and a $21 price target. The firm says data center developers are turning to gas engines for their own power because grid connections can take six years or more and turbines are sold out. INNIO is a global energy technology company that serves industrial, commercial, utility and infrastructure customers. It builds the Jenbacher gas engines and sells services over their lives, including long-term service agreements, spare parts and overhauls. Its equipment segment sells new engines and related equipment for data centers, power solutions and compression.

The third quarter of 2026, reported on October 27, was the company’s first with more than $1 billion in revenue, which reached $1.17 billion, up 57% from a year earlier. Data center revenue was $463 million. The pull from that market is also the subject of a piece we wrote on a mystery buyer’s 450-megawatt bet on INNIO’s gas engines.

Piper Sandler estimates INNIO will sell about 6 gigawatts to data centers over two years. That volume underpins its 2028 estimates of $6.25 billion in revenue and $1.45 billion in adjusted EBITDA.

1. Ultra Clean (NASDAQ:UCTT)

Average Upside Potential: 128%

Number of Hedge Fund Holders: 44

Barclays initiated coverage of Ultra Clean (NASDAQ:UCTT) on November 13 with an Equal Weight rating and a $65 price target, tying the company to a forecast surge in spending on chip equipment. Barclays expects wafer fab equipment spending to grow 32% in 2027 and 21% in 2028, and it says Ultra Clean’s results track that spending closely.

Ultra Clean designs and makes production tools, modules and subsystems for the semiconductor and display equipment industry. It supplies critical subsystems, components and parts to the semiconductor equipment industry and runs ultra-high purity cleaning services for chipmaking parts, including recoating of process tool parts and surface encapsulation. Applied Materials and Lam Research together account for most of its revenue, so its fortunes depend on two customers.

The third quarter of 2026, which ended September 25 and was reported on October 27, set a record. Revenue reached $759 million, up 49% from the third quarter of 2025, and the company guided to $800 million to $860 million for the fourth quarter of 2026. Under its at-the-market program, Ultra Clean sold new shares worth $169.1 million through October 28.

READ NEXT: Could Cadence Design (CDNS) and Analog Devices (ADI) Capture More of the Smart-Vehicle Opportunity? and Korn Ferry (KFY) Grew Contracted Fees 14%. Can AMS Add Growth Without Squeezing Margins?

Follow Insider Monkey on Google News.

Page 3 of 3